UPDATED March 31, 2014, with comment from Medtronic
Welcome to the latest edition of the MassDevice.com’s D+Vice Talk, our new webcast, in which we review medical device stories from the last week.
In this episode we start with updates from Capitol Hill, review highlights from the American College of Cardiology conference, consider the mixed FDA reports for Abbott’s MitraClip heart implant and debate Dr. Robert Hauser’s controversial proposal to overhaul the FDA.
Find all of today’s referenced stories here:
Sometimes the major annual medical meetings are jam-packed with significant and market-moving data. And then sometimes they’re like this year’s American College of Cardiology conference, with relatively limited useful data from an investing perspective.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Renal denervation technologies, which are already the focus of much clinical attention for the potential to treat high blood pressure without drugs, may have a bonus side-effect in keeping the heart in check, according to researchers.